New Research Showing Actos Possibly Beneficial for Depression Could Lead to More Cases of Bladder Cancer

Share Article

The Actos Resource Center is the the Web’s largest source for information on Actos research, side effects and legal news. Visit

Actos lawsuit
It was recently discovered that Actos may enhance the effects of antidepressants in treating Major Depressive Disorder.

The Actos Resource Center, a bladder cancer patient advocacy group, is alerting patients that new research published this month in the journal Neuropsychopharmacology indicates Actos might be helpful in treating depression, however, this could also increase the risk of patients developing bladder cancer.

Actos is a popular treatment for type II diabetes. Although it has been associated with bladder cancer by researchers in France, Germany, Canada and the United States, scientists also recently discovered it may enhance the effects of antidepressants in treating Major Depressive Disorder.

The research, published last week in the journal Neuropsychopharmacology, was collected by scientists at Tehran University in Iran. Following 40 patients over a 6 week period, they found that those given Actos in conjunction with antidepressant medications reported more symptom relief.

Professor Shahin Akhondzadeh commented that the results were important since a large percentage of patients treated for depression fail to respond to the available antidepressant medications.

Advocates at the Actos resource center, however, are concerned that the results will lead to more doctors prescribing Actos off-label to aid in the treatment of depression, putting more at risk of bladder cancer. In June of 2011, the FDA warned that the drug may be associated with increased risks of bladder cancer.

CBS News reported on June 10, 2011 that Germany and France had banned Actos after a study indicated long-term use could increase bladder cancer occurrences by as much as 40%. The Canadian Press also reported on April 19, 2012 that Health Canada had issued a warning after a study there showed a greater than 40% increased risk of the disease from Actos.

According to a Bloomberg report on March 13, 2012, Takeda Pharmaceuticals and Eli Lilly face as many as 10,000 Actos lawsuits from patients in the U.S. over bladder cancer allegedly caused by the drug.

A federal Judicial Panel on Multidistrict Litigation has consolidated all of the lawsuits into a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center cautions anyone considering taking Actos to speak with their doctor about the risks. Anyone diagnosed with bladder cancer after taking the drug should speak with a lawyer about their legal rights.

The Actos Bladder Cancer Center only works with qualified Actos lawyers who are actively involved in this litigation and have handled thousands of cases.

For more information on the research, warnings, side effects and legal options relating to the drug Actos, or to speak with a lawyer, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Schroeder
Visit website